Goal is to develop novel treatment for autoimmune diseases.

Eden Biodesign has been selected by the University of Birmingham to develop and produce vOX2:Fc, a therapeutic candidate for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The university’s David Blackbourn, Ph.D., has been investigating the molecule.

“Working with Eden Biodesign will allow us to advance our understanding of the therapeutic potential of this drug candidate; clinical applications for this novel therapy could range from autoimmune diseases such as rheumatoid arthritis to asthma and allergy,” notes Dr. Blackbourn.

Previous articleGSK and Targacept Ink $1.5B Pact
Next articleVivus Eligible to Receive Milestone Payment of $140M from KV Pharmaceutical